The functional importance of the N-terminal epidermal growth factor-like domain (EGF-N) of factor X/Xa (FX/Xa) was investigated by constructing an FX mutant in which the exon coding for EGF-N was deleted from FX cDNA. Following expression and purification to homogeneity, the mutant was characterized with respect to its ability to function as a zymogen for either the factor VIIa-tissue factor complex or the factor IXa-factor VIIIa complex; and then to function as an enzyme in the prothrombinase complex to catalyze the conversion of prothrombin to thrombin. It was discovered that EGF-N is essential for the recognition and efficient activation of FX by both activators in the presence of the cofactors. On the other hand, the FXa mutant interacted with factor Va with a normal apparent dissociation constant and activated prothrombin with ∼3-fold lower catalytic efficiency in the prothrombinase complex. Surprisingly, the mutant activated prothrombin with ∼12-fold better catalytic efficiency than wild-type FXa in the absence of factor Va. The mutant was inactive in both PT and aPTT assays, however, it exhibited a similar specific activity in a one-stage FXa clotting assay. These results suggest that EGF-N of FX is required for the cofactor-dependent zymogen activation by both physiological activators, but it plays no apparent role in FXa recognition of the cofactor in the prothrombinase complex.
INTRODUCTION
that the Gla and/or EGF-N domains of FXa contribute ∼10-fold to the affinity of the cofactor interaction (33) . The reason for these contradictory results is not known.
To further investigate the role of the EGF-N domain of FX/Xa by a different approach, we constructed a deletion mutant of FX in which the exon coding for EGF-N was deleted from FX cDNA.
This mutant was expressed in mammalian cells and purified to homogeneity as described (34) . Unlike the previous mutant lacking both the Gla and EGF-N (E2-FX) (31), this mutant contains an intact Gladomain, thus, the zymogenic and enzymatic properties of this mutant could be characterized in appropriate activation complexes on phospholipid vesicles. In this study, we present data which suggest that the EGF-N domain of FX is required for the zymogen activation by both the extrinsic and intrinsic Xase complexes. On the other hand, the FXa mutant interacted with factor Va with a similar affinity on phospholipid vesicles and activated prothrombin with ∼3-fold impaired catalytic efficiency. Interestingly, the mutant activated prothrombin with ~12-fold better catalytic efficiency in the absence of factor Va and exhibited a similar or better specific activity in a one-stage FXa clotting assay, though it was inactive in both PT and aPTT assays. These results suggest an important role for EGF-N in recognition and activation of FX by both physiological activators, but this domain appears not to have a specific role in FXa recognition of factor Va in the prothrombinase complex. The implication of these findings for the spacer function of FX/Xa within the activation complexes is discussed.
EXPERIMENTAL PROCEDURES

Mutagenesis and Expression of Recombinant Proteins-Construction and expression of wild-type
FX in an expression/purification vector system has been described previously (34) . The EGF-N deletion mutant of FX, lacking the exon coding for the N-terminus EGF domain of FX (FX-desEGF-N), was prepared by PCR mutagenesis methods in the same vector system as described (34) . After confirmation of the accuracy of the mutagenesis by DNA sequencing, the constructs containing either wild-type or mutant FX cDNA were transfected into HEK293 cells and the recombinant proteins were isolated from cell culture supernatants by a combination of immunoaffinity and ion exchange chromatography using the HPC4 monoclonal antibody and a Mono Q FPLC column as described (34) . Recombinant soluble tissuefactor (sTF), and TF lacking the cytoplasmic domain (dcTF), both purified from bacteria (35, 36) , were kindly provided by Dr. James Morrissey (University of Illinois at Urbana-Champaign).
Human plasma proteins including antithrombin, factors Va, VIIa, IXa, Xa and X and the factor Xactivating enzyme from Russell's viper venom (RVV-X) were purchased from Haematologic Technologies Inc. (Essex Junction, VT). Human factor VIIIa was a generous gift from Dr. Philip Fay (University of Rochester, NY). Phospholipid vesicles containing 80% phosphatidylcholine and 20% phosphatidylserine (PC/PS) were prepared as described (37) . The incorporation of dcTF into PC/PS vesicles has been described previously (36) . The chromogenic substrate Spectrozyme FXa (SpFXa) was purchased from American Diagnostica (Greenwich, CT), and S2238 was purchased from Kabi Pharmacia/Chromogenix (Franklin, OH Activation by the Factor VIIa-TF Complex-The initial rate of concentration dependence of FX activation on PC/PS vesicles was studied in both the absence and presence of soluble TF (sTF) and dcTF incorporated into PC/PS vesicles as described (35, 36) . Briefly, the activation of increasing concentrations of the wild-type and mutant FX (7.8-2600 nM) by factor VIIa (20 nM in the absence of and 0.025-1.0 nM in the presence of TF) was monitored in the absence or presence of a saturating concentration of sTF (250 nM) and relipidated dcTF (2 nM) in TBS/Ca 2+ for 1-30 min at room temperature in 30 µL reactions in 96-well assay plates. The activation reactions were terminated by an addition of 20 µL EDTA to obtain a final concentration of 20 mM. The concentration of FXa generated was determined from standard curves by a chromogenic substrate assay as described above. The K m and k cat values for the activation reactions were calculated as described above.
Activation by RVV-X and Amidolytic Activity-To evaluate the catalytic properties of the FXa mutant, 500 µL of 2 µM wild-type or mutant zymogen was incubated with 20 nM RVV-X in TBS/Ca 2+ for 2 h at 37 o C. To separate the snake venom, the activation reactions were individually applied on a engineered to the N-terminal end of the activation peptide, thus, activated FX does not bind to the column (34) . Since the zymogen FX binds to the column, the flow through of this purification step contains only activated protein. Thus, both unbound wild-type and mutant FXa from the HPC4 column were pooled, concentrated, and active-site titrated by stoichiometric titrations with known concentrations of antithrombin as described (38) . The steady-state kinetics of hydrolysis of SpFXa (7.8-1000 µM) by the wild-type and mutant FXa (1 nM) were studied in TBS/Ca 2+ and the K m and k cat values for substrate hydrolysis were calculated from the Michaelis-Menten equation as described above.
Activation of Prothrombin-The initial rate of prothrombin activation by the wild-type and mutant FXa was determined in both the absence and presence of factor Va at room temperature on PC/PS vesicles as described (34) . In the absence of the cofactor, prothrombin (10-2500 nM) was incubated with either wild-type or mutant FXa (2.5 nM) in TBS/Ca 2+ on PC/PS vesicles (35 µM). Following 5 min incubation at room temperature, the rate of thrombin generation was measured by an amidolytic activity assay using 100 µM S2238. The concentrations of thrombin generated in the activation reactions were determined from a standard curve prepared from the cleavage rate of S2238 by known concentrations of thrombin under exactly the same conditions. The initial rate of prothrombin activation in the presence of human factor Va (25 nM) was measured by incubating each FXa derivative (25-100 pM) with increasing concentrations of prothrombin (7.8-1000 nM) in TBS/Ca 2+ on PC/PS vesicles (35 µM). Following 0.5-2 min incubation at room temperature, EDTA was added to a final concentration of 20 mM and the concentration of thrombin generated was determined from a standard curve as described above. It was ensured that less than 15% of prothrombin was activated at all concentrations of the substrate.
The cofactor dependence of prothrombin activation by FXa was also used to evaluate the apparent affinity of factor Va for the wild-type and mutant FXa. In this case, the activation of a fixed concentration of prothrombin (1 µM) by wild-type or mutant FXa (100 pM) was monitored in the presence of increasing concentrations of human factor Va (0.3-20 nM) on PC/PS vesicles (35 µM). The activation reactions were carried out at room temperature for 0.5-2 min after which EDTA was added to a final concentration of 20 mM and the apparent dissociation constants were determined from the cofactordependent rate of thrombin generation as described (20) . The same assay was also used to evaluate the apparent affinity of FXa derivatives for interaction with PC/PS vesicles. In this case, the activation of prothrombin or prethrombin-1 (prothrombin lacking both Gla and kringle-1 domains) (1 µM) by FXa 
RESULTS
Expression and Purification of Recombinant
Proteins-Both the wild-type and mutant FX were expressed in human 293 cells as described under "Experimental Procedures". Recombinant proteins were separated from the cell culture supernatants by immunoaffinity chromatography using the HPC4 monoclonal antibody as described previously (34) . Further purification on a Mono Q column was required to separate the fully and partially γ-carboxylated proteins as described (34, 38) . SDS-PAGE analysis of the purified proteins in both zymogen and active forms under non-reducing conditions indicated that both recombinant FX and the mutant have been purified to homogeneity (data not shown).
The wild-type and mutant FX zymogens migrated with the expected relative molecular masses of ∼60 kDa and ∼55 kDa, and following activation with the expected molecular masses of ∼45 and ∼40 kDa, respectively (data not shown).
FX Activation by the Intrinsic Xase Complex-
The zymogenic properties of wild type and mutant FX were evaluated in kinetic studies by factor IXa in both the absence and presence of factor VIIIa and Ca 2+ on PC/PS vesicles (intrinsic Xase complex). The concentration dependence of the activation reactions suggested that factor IXa by itself activates both FX derivatives with similar k cat values, however, K m(app) for activation of the mutant was elevated ∼10-fold ( Figure 1A , Table 1 ). Interestingly, a similar ∼10-fold impairment in the K m(app) value with the mutant was also observed in the presence of factor VIIIa ( Figure 1B , Table 1 ). However, unlike the similar k cat values in the absence of factor VIIIa, the k cat for the activation of the mutant was also impaired nearly 20-fold ( Figure 1B , Table 1 ). These results suggest that the catalytic efficiency of the intrinsic Xase complex toward the activation of the FX mutant has been impaired ∼200-fold. Thus, the N-terminal domain of FX plays a crucial role in substrate activation by factor IXa in both the absence and presence of the cofactor. A previous study with a chimeric FX mutant which contained the Gla and EGF-N domains of factor IX demonstrated that neither domain of FX contributes to recognition of the protease or the cofactor in the intrinsic Xase complex (33) .
Thus, assuming that EGF-N of factor IX in the chimeric molecule did not functionally substitute for a potential interactive site of FX in the intrinsic Xase complex, the results here would implicate an important spacer function for EGF-N in FX activation by the intrinsic Xase complex.
Activation by the Extrinsic Xase Complex-
The zymogenic properties of the FX mutant were also evaluated in kinetic studies by factor VIIa in both the absence and presence of TF and Ca 2+ on PC/PS vesicles (extrinsic Xase complex). In the absence of a cofactor, factor VIIa activated both wild type and mutant FX with a similar catalytic efficiency on PC/PS vesicles ( Figure 2A inset and 2B, Table 1 ).
Consistent with previous results, soluble TF (sTF) dramatically accelerated the activation of wild-type FX by factor VIIa (Figure 2A) . Interestingly, however, sTF negatively affected the activation of FX-desEGF-N by factor VIIa as evidenced by an ∼5-fold elevated K m(app) in the presence of the cofactor ( Figure 2B ).
With the relipidated TF, relative to activation of wild-type FX ( Figure 3A ), the catalytic efficiency of factor VIIa toward FX-desEGF-N was impaired more than 4200-fold (Figure, 3B, Table 1 ). Unlike sTF, relipidated TF improved the catalytic efficiency of factor VIIa toward the FX mutant ∼100-fold (compare Figures 2B and 3B ). The dramatic impairment in activation of the mutant was caused by an ∼19-fold elevated K m(app) and ∼220-fold decreased k cat values (Table 1) . These results suggest that the N-terminal EGF domain of FX plays a critical role in FX activation by the extrinsic Xase complex. The observation that factor VIIa in the absence of a cofactor activates both wild-type and mutant FX at similar rates, further suggests that EGF-N does not interact with the protease but interacts with the cofactor and/or has a spacer function in the extrinsic Xase complex (see below).
Previous mutagenesis data have indicated that the Gla domain of FX interacts with a basic region in the membrane proximal C-terminal domain of TF (25, 26) . To determine whether the impaired catalytic efficiency of the factor VIIa-sTF complex toward the FX mutant is due to an unproductive complex formation, the ability of the FX mutant to act as a competitive inhibitor of wild-type FX activation by the extrinsic Xase complex was evaluated. As shown in Figure 4 , FX-desEGF-N effectively inhibited the activation of FX by the extrinsic Xase complex with a K d(app) of ∼200 nM. These results support the hypothesis that the EGF-N domain of FX has an important spacer function in substrate activation by the extrinsic Xase complex, and that its deletion changes the topographical arrangement of the cleavage site in the activation complex.
Catalytic Properties of FXa-desEGF-N-
To study the role of EGF-N in the catalytic function of FXa, the mutant was characterized with respect to its ability to hydrolyze SpFXa, react with antithrombin, and interact with factor Va to activate prothrombin in the prothrombinase complex.
Amidolytic Activity and reaction with Antithrombin-Kinetic parameters for the hydrolysis of the chromogenic substrate SpFXa by both wild-type and mutant FXa are presented in Table 2 Table 2 ). The primary catalytic defect with the mutant protease was localized in the k cat of the activation reaction (Table 2) Clotting Assays-Both PT and aPTT assays were used to evaluate the clotting activities of wildtype and mutant zymogens as described previously (38) . Unlike a clotting time of ~17 sec for wild-type FX at a final concentration of 1.6 µg/mL in PT assay, no clotting activity was observed for the FX mutant at up to 20 µg/mL zymogen (data not shown). The same results were also observed in the aPTT assay (data not shown). Thus, consistent with results in the purified systems, the EGF-N domain of FX is required for recognition and activation of the substrate by both the extrinsic and intrinsic Xase complexes.
The clotting activities of wild-type and mutant proteases were also evaluated in the one-stage FXa clotting assay. Interestingly, the FXa mutant exhibited identical or better specific activity in this assay ( Figure 7 ) supporting the kinetic data in the purified system that EGF-N of FXa plays a minor role in the prothrombinase complex. The improvement in the clotting activity of the mutant FXa is likely due to the ability of the mutant to activate prothrombin with markedly improved rate constant in the absence of the
DISCUSSION
In light of the lack of x-ray crystallographic data for the ternary coagulation protease-cofactorsubstrate complexes, mutagenesis is a powerful approach in dissecting the molecular determinants of the coagulation protease specificity on negatively charged membrane surfaces. In particular, domain swabbing has proved to be an attractive approach for studying this problem in vitamin K-dependent coagulation proteases/zymogens, because these molecules have similar genetic organizations with an equal number of exons, each coding for a distinct structural and/or functional domain in these proteins Unlike normal activation by factor VIIa in the absence of TF, the activation of the FX mutant by factor IXa was impaired in both the absence and presence of factor VIIIa. In this case, the extent of impairment was ∼10-fold elevated K m(app) in both the absence and presence of factor VIIIa and ∼20-fold Table 2 . Kinetic parameters for the hydrolysis of the chromogenic substrate SpFXa (7.8-1000 µM) by wild-type or mutant FXa (1 nM each) was determined in TBS/Ca 2+ as described under "Experimental Procedures".
Kinetic parameters for the activation of prothrombin by both wild-type and mutant FXa (2.5 nM in the absence of factor Va and 25-100 pM in the presence of 25 nM factor Va) were determined on PC/PS vesicles (35 µM) as a function of increasing concentrations of prothrombin (10-2500 nM) in TBS/Ca 2+ at room temperature as described under "Experimental Procedures". All values are the average of 2-3 independent measurements ± S.E.
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